Unveiling Myeloid Transformation: T‐LGLL with Eosinophilia Masking Myeloid‐associated STAT5B Mutation Culminating in AML
Qianze Dong,Yang Wang,Yan Xiu,Xiaogang Wu,Stacey O'Neill,Howard Meyerson,Suske Tobias,Richard Moriggl,Shimin Hu,Wei Wang,Chen Zhao
DOI: https://doi.org/10.1111/bjh.19421
2024-01-01
British Journal of Haematology
Abstract:British Journal of HaematologyEarly View LETTER TO THE EDITOR Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML Qianze Dong, Qianze Dong Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYang Wang, Yang Wang Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYan Xiu, Yan Xiu Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorXiaogang Wu, Xiaogang Wu Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorStacey O'Neill, Stacey O'Neill Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorHoward Meyerson, Howard Meyerson Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorSuske Tobias, Suske Tobias Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorRichard Moriggl, Richard Moriggl Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorShimin Hu, Shimin Hu orcid.org/0000-0001-7110-3814 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorWei Wang, Corresponding Author Wei Wang [email protected] orcid.org/0000-0001-6821-4556 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this authorChen Zhao, Corresponding Author Chen Zhao [email protected] orcid.org/0000-0003-3217-0269 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA Department of Medicine, Section of Hematology, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this author Qianze Dong, Qianze Dong Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYang Wang, Yang Wang Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorYan Xiu, Yan Xiu Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USASearch for more papers by this authorXiaogang Wu, Xiaogang Wu Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorStacey O'Neill, Stacey O'Neill Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorHoward Meyerson, Howard Meyerson Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USASearch for more papers by this authorSuske Tobias, Suske Tobias Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorRichard Moriggl, Richard Moriggl Institute of Animal Breeding and Genetics, University of Veterinary Medicine, Vienna, AustriaSearch for more papers by this authorShimin Hu, Shimin Hu orcid.org/0000-0001-7110-3814 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USASearch for more papers by this authorWei Wang, Corresponding Author Wei Wang [email protected] orcid.org/0000-0001-6821-4556 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this authorChen Zhao, Corresponding Author Chen Zhao [email protected] orcid.org/0000-0003-3217-0269 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA Department of Medicine, Section of Hematology, Louis Stokes Veterans Affairs Medical Center, Cleveland, Ohio, USA Correspondence Wei Wang, Department of Hematopathology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Email: [email protected] Chen Zhao, Department of Pathology, Case Western Reserve University, Wolstein Research Building, Room 6532, 2103 Cornell Road, Cleveland, OH 44106-7288, USA. Email: [email protected]Search for more papers by this author First published: 20 March 2024 https://doi.org/10.1111/bjh.19421Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Supporting Information Filename Description bjh19421-sup-0001-supinfo.docxWord 2007 document , 22.4 KB Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Smith MR, Satter LRF, Vargas-Hernandez A. STAT5b: a master regulator of key biological pathways. Front Immunol. 2022; 13:1025373. 10.3389/fimmu.2022.1025373 CASPubMedWeb of Science®Google Scholar 2Kollmann S, Grausenburger R, Klampfl T, Prchal-Murphy M, Bastl K, Pisa H, et al. A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood. 2021; 138(23): 2347–2359. 10.1182/blood.2021010980 CASPubMedWeb of Science®Google Scholar 3Ariyoshi K, Nosaka T, Yamada K, Onishi M, Oka Y, Miyajima A, et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J Biol Chem. 2000; 275(32): 24407–24413. 10.1074/jbc.M909771199 CASPubMedWeb of Science®Google Scholar 4Ma CA, Xi L, Cauff B, DeZure A, Freeman AF, Hambleton S, et al. Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. Blood. 2017; 129(5): 650–653. 10.1182/blood-2016-09-737817 CASPubMedWeb of Science®Google Scholar 5Pham HTT, Maurer B, Prchal-Murphy M, Grausenburger R, Grundschober E, Javaheri T, et al. STAT5BN642H is a driver mutation for T cell neoplasia. J Clin Invest. 2018; 128(1): 387–401. 10.1172/JCI94509 PubMedWeb of Science®Google Scholar 6Cross NCP, Hoade Y, Tapper WJ, Carreno-Tarragona G, Fanelli T, Jawhar M, et al. Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. Leukemia. 2019; 33(2): 415–425. 10.1038/s41375-018-0342-3 CASPubMedWeb of Science®Google Scholar 7de Araujo ED, Erdogan F, Neubauer HA, Meneksedag-Erol D, Manaswiyoungkul P, Eram MS, et al. Structural and functional consequences of the STAT5B(N642H) driver mutation. Nat Commun. 2019; 10(1): 2517. 10.1038/s41467-019-10422-7 PubMedWeb of Science®Google Scholar 8Rajala HL, Eldfors S, Kuusanmäki H, van Adrichem A, Olson T, Lagström S, et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood. 2013; 121(22): 4541–4550. 10.1182/blood-2012-12-474577 CASPubMedWeb of Science®Google Scholar 9Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, et al. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. Blood. 2016; 128(20): 2465–2468. 10.1182/blood-2016-06-724856 CASPubMedWeb of Science®Google Scholar 10Kucuk C, Jiang B, Hu X, Zhang W, Chan JKC, Xiao W, et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun. 2015; 6: 6025. 10.1038/ncomms7025 CASPubMedWeb of Science®Google Scholar 11Kavesh M, Mohebnasab M, Angel MR, Xie W, Raess PW, Cui W, et al. Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling. Blood Adv. 2023; 7(1): 40–45. 10.1182/bloodadvances.2022008192 CASPubMedWeb of Science®Google Scholar 12Sreedharanunni S, Jamwal M, Balakrishnan A, Aravindan AV, Sharma R, Singh N, et al. Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation—an entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap. Leuk Res. 2022; 112:106753. 10.1016/j.leukres.2021.106753 CASPubMedWeb of Science®Google Scholar 13Qu S, Jia Y, Wang H, Ai X, Xu Z, Qin T, et al. STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms. Leuk Lymphoma. 2021; 62(6): 1506–1509. 10.1080/10428194.2020.1869964 CASPubMedWeb of Science®Google Scholar 14Lamy T, Moignet A, Loughran TP Jr. LGL leukemia: from pathogenesis to treatment. Blood. 2017; 129(9): 1082–1094. 10.1182/blood-2016-08-692590 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation